Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-26 @ 11:09 AM
Ignite Modification Date: 2025-12-26 @ 11:09 AM
NCT ID: NCT04146012
Description: None
Frequency Threshold: 5
Time Frame: Data was collect over 26 week period
Study: NCT04146012
Study Brief: BEACH Trial: Bovine Early Access, Compatibility and Hemostasis Trial
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Early Access Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed in less than 72 hours after implantation. Artegraft® Collagen Vascular Graft™ (Artegraft): The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft. 0 None 0 3 0 3 View
Normal Access Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed after 10 days as per current IFU. Artegraft® Collagen Vascular Graft™ (Artegraft): The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft. 0 None 0 3 0 2 View
Serious Events(If Any):
Other Events(If Any):